These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 30927153)

  • 1. A Systematic Review and Evaluation of Clinical Practice Guidelines for Children and Youth with Disruptive Behavior: Rigor of Development and Recommendations for Use.
    Andrade BF; Courtney D; Duda S; Aitken M; Craig SG; Szatmari P; Henderson J; Bennett K
    Clin Child Fam Psychol Rev; 2019 Dec; 22(4):527-548. PubMed ID: 30927153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 1: psychostimulants, alpha-2 agonists, and atomoxetine.
    Pringsheim T; Hirsch L; Gardner D; Gorman DA
    Can J Psychiatry; 2015 Feb; 60(2):42-51. PubMed ID: 25886655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 2: antipsychotics and traditional mood stabilizers.
    Pringsheim T; Hirsch L; Gardner D; Gorman DA
    Can J Psychiatry; 2015 Feb; 60(2):52-61. PubMed ID: 25886656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Canadian guidelines on pharmacotherapy for disruptive and aggressive behaviour in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, or conduct disorder.
    Gorman DA; Gardner DM; Murphy AL; Feldman M; Bélanger SA; Steele MM; Boylan K; Cochrane-Brink K; Goldade R; Soper PR; Ustina J; Pringsheim T
    Can J Psychiatry; 2015 Feb; 60(2):62-76. PubMed ID: 25886657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atypical antipsychotics for disruptive behaviour disorders in children and youths.
    Loy JH; Merry SN; Hetrick SE; Stasiak K
    Cochrane Database Syst Rev; 2012 Sep; (9):CD008559. PubMed ID: 22972123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards high-quality, useful practice guidelines for child and youth mental health disorders: protocol for a systematic review and consensus exercise.
    Bennett K; Duda S; Brouwers M; Szatmari P; Newton A; McLennan J; Sundar P; Cleverley K; Charach A; Henderson J; Courtney D; Rice M
    BMJ Open; 2018 Feb; 8(2):e018053. PubMed ID: 29437752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ADHD with comorbid oppositional defiant disorder or conduct disorder: discrete or nondistinct disruptive behavior disorders?
    Connor DF; Doerfler LA
    J Atten Disord; 2008 Sep; 12(2):126-34. PubMed ID: 17934178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of aggressive ADHD in children and adolescents: conceptualization and treatment of comorbid behavior disorders.
    McBurnett K; Pfiffner LJ
    Postgrad Med; 2009 Nov; 121(6):158-65. PubMed ID: 19940426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practice parameter for the assessment and treatment of children and adolescents with oppositional defiant disorder.
    Steiner H; Remsing L;
    J Am Acad Child Adolesc Psychiatry; 2007 Jan; 46(1):126-141. PubMed ID: 17195736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Appraisal of clinical practice guidelines for the management of attention deficit hyperactivity disorder (ADHD) using the AGREE II Instrument: A systematic review.
    Amer YS; Al-Joudi HF; Varnham JL; Bashiri FA; Hamad MH; Al Salehi SM; Daghash HF; Albatti TH;
    PLoS One; 2019; 14(7):e0219239. PubMed ID: 31276528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disruptive Mood Dysregulation Disorder in a Community Mental Health Clinic: Prevalence, Comorbidity and Correlates.
    Freeman AJ; Youngstrom EA; Youngstrom JK; Findling RL
    J Child Adolesc Psychopharmacol; 2016 Mar; 26(2):123-30. PubMed ID: 26745325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reliability and validity of teacher-rated symptoms of oppositional defiant disorder and conduct disorder in a clinical sample.
    Ise E; Görtz-Dorten A; Döpfner M
    Psychopathology; 2014; 47(5):312-8. PubMed ID: 24993973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups.
    Jensen PS; Hinshaw SP; Kraemer HC; Lenora N; Newcorn JH; Abikoff HB; March JS; Arnold LE; Cantwell DP; Conners CK; Elliott GR; Greenhill LL; Hechtman L; Hoza B; Pelham WE; Severe JB; Swanson JM; Wells KC; Wigal T; Vitiello B
    J Am Acad Child Adolesc Psychiatry; 2001 Feb; 40(2):147-58. PubMed ID: 11211363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The long-term longitudinal course of oppositional defiant disorder and conduct disorder in ADHD boys: findings from a controlled 10-year prospective longitudinal follow-up study.
    Biederman J; Petty CR; Dolan C; Hughes S; Mick E; Monuteaux MC; Faraone SV
    Psychol Med; 2008 Jul; 38(7):1027-36. PubMed ID: 18205967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experiences of physical and relational victimization in children with ADHD: The role of social problems and aggression.
    McQuade JD; Breslend NL; Groff D
    Aggress Behav; 2018 Jul; 44(4):416-425. PubMed ID: 29659017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A process for developing community consensus regarding the diagnosis and management of attention-deficit/hyperactivity disorder.
    Foy JM; Earls MF
    Pediatrics; 2005 Jan; 115(1):e97-104. PubMed ID: 15629972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementing the American Academy of Pediatrics attention-deficit/hyperactivity disorder diagnostic guidelines in primary care settings.
    Leslie LK; Weckerly J; Plemmons D; Landsverk J; Eastman S
    Pediatrics; 2004 Jul; 114(1):129-40. PubMed ID: 15231919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attendance and Engagement in Parent Training Predict Child Behavioral Outcomes in Children Pharmacologically Treated for Attention-Deficit/Hyperactivity Disorder and Severe Aggression.
    Joseph HM; Farmer C; Kipp H; Kolko D; Aman M; McGinley J; Arnold LE; Gadow KD; Findling RL; Molina BSG
    J Child Adolesc Psychopharmacol; 2019 Mar; 29(2):90-99. PubMed ID: 30592635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
    Dittmann RW; Schacht A; Helsberg K; Schneider-Fresenius C; Lehmann M; Lehmkuhl G; Wehmeier PM
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):97-110. PubMed ID: 21488751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bifactor latent structure of attention-deficit/hyperactivity disorder (ADHD)/oppositional defiant disorder (ODD) symptoms and first-order latent structure of sluggish cognitive tempo symptoms.
    Lee S; Burns GL; Beauchaine TP; Becker SP
    Psychol Assess; 2016 Aug; 28(8):917-28. PubMed ID: 26502205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.